Takeda to take back Replagal rights

26 November 2021

Japanese drug majors Takeda Pharmaceutical (TYO: 4502) and Sumitomo Dainippon Pharma (TYO: 4506) announced today that Takeda will succeed the manufacturing and marketing approval and the marketing rights of Replagal (agalsidase alfa) for Fabry disease, an α-galactosidase enzyme intravenous (IV) infusion, as of February 15, 2022.

Shares of Sumitomo Dainippon Pharma closed down 3.2% at 2,435 yen following the announcement

Replagal was originally developed by Shire, which Takeda acquired for around $62 billion in 2019, at which stage the drug was generating annual global sales nearly $500 million for the UK firm. For the last full year fiscal period, Sumitomo Dainippon recorded around $120 million for the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK